EMVision expands FDA trial scope for stroke detection device. The ASX-listed biotech company is broadening its pivotal FDA De Novo trial to include acute ischaemia detection alongside its original haemorrhage detection focus. Trial recruitment has exceeded 125 patients with no adverse events reported, with full enrolment expected by late 2026 or early 2027. The company maintains AUD 18.4 million in cash reserves plus recent non-dilutive CRC-P funding of AUD 0.4 million. While the ischaemia endpoint adds regulatory complexity and execution uncertainty, the expanded indication could significantly broaden the commercial potential of the emu device and potentially accelerate market access. Success requires validation of the new detection capability.
Post from MarketNews_en
Log in to interact with content.